Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Biogen

Patients’ groups, progressives square off over Medicare Alzheimer’s decision

WASHINGTON — Advocates on both sides of a debate over dramatically restricting Medicare’s coverage of an expensive and controversial Alzheimer’s treatment are waging competing campaigns to influence a final decision in April.

Tribune News Service

Patients' groups, progressives square off over Medicare Alzheimer's decision - Roll Call

Patients' groups, progressives square off over Medicare Alzheimer's decision - Roll Call

Competing campaigns look to influence the debate over dramatically restricting coverage of a controversial treatment drug Aduhelm.

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane

Biogen Inc (NASDAQ: BIIB) and Xbrane Biopharma AB have

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis Biosimilar

Here's a roundup of top developments in the biotech space over the last 24 hours:

Biogen's Aduhelm Approval, Marketing Comes Under FTC, SEC Probes

The Federal Trade Commission (FTC) and the Securities and Exchange Commission (SEC) have launched two separate investigations into Biogen Inc (NASDAQ: BIIB) and its Alzheimer's med, Aduhelm (aducanumab).

What 24 Analyst Ratings Have To Say About Biogen

Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings:

Analyst Ratings For Biogen

Analysts have provided the following ratings for Biogen (NASDAQ:BIIB) within the last quarter:

inkl

Read news from The Economist, FT, and more,
with one subscription

Biogen's Return On Capital Employed Insights

Biogen's Return On Capital Employed Insights

Benzinga Pro data, Biogen (NASDAQ:BIIB) reported Q4 sales of $2.73 billion. Earnings fell to a loss of $20.50 million, resulting in a 106.44% decrease from last quarter. In Q3, Biogen earned $318.10 million, and total sales reached $2.78 billion.

Biogen's Alzheimer's Drug Clocks Q4 Sales Of Just $1M, FY22 Earnings Guidance Below Consensus

Biogen's Alzheimer's Drug Clocks Q4 Sales Of Just $1M, FY22 Earnings Guidance Below Consensus

Biogen Inc (NASDAQ: BIIB) posted Q4 sales of 2.73 billion, beating the consensus of $

Biogen: Q4 Earnings Insights

Biogen: Q4 Earnings Insights

Biogen (NASDAQ:BIIB) reported its Q4 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Why Biogen Shares Are Sliding Today

Why Biogen Shares Are Sliding Today

Biogen Inc (NASDAQ: BIIB) is trading lower Thursday morning after the company announced worse-than-expected fourth-quarter earnings results and issued guidance below estimates.

Biogen's Alzheimer's Struggles Continue; 'Minimal' Sales Expected This Year

Biogen's Alzheimer's Struggles Continue; 'Minimal' Sales Expected This Year

Biogen stock tumbled Thursday after the biotech company guided to "minimal" 2022 sales of its Alzheimer's drug, Aduhelm.

Investors Business Daily

Biogen's 2022 outlook leaves investors wanting, shares slip

Biogen's 2022 outlook leaves investors wanting, shares slip

Biogen expects “minimal” revenue this year from its Alzheimer’s treatment initially hailed as potentially a breakthrough drug, but one with an eye-popping price tag that drew immediate criticism from doctors and patient advocates

The Independent UK

Recap: Biogen Q4 Earnings

Recap: Biogen Q4 Earnings

Biogen (NASDAQ:BIIB) reported its Q4 earnings results on Thursday, February 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100’s of premium titles.
One news app.

Earnings Preview For Biogen

Biogen (NASDAQ:BIIB) is set to give its latest quarterly earnings report on Thursday, 2022-02-03. Here's what investors need to know before the announcement. Analysts estimate that Biogen will likely report an Earnings Per Share (EPS) of $3.40.

Biogen Exercises Option To Participate Developing Genentech's Bispecific Antibody, Mosunetuzumab

Biogen Inc (NASDAQ: BIIB) has

Investors Business Daily

Biogen Snags $2.3 Billion In Samsung Biosimilars Deal; So, What's Next?

Biogen stock popped Friday after the company agreed to sell its stake in a Samsung biosimilars venture for $2.3 billion.

The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron

Here's a roundup of top developments in the biotech space over the last 24 hours:

Get all your
news in one place.

100’s of premium titles.
One news app.

Biogen Sells Biosimilar-Venture Stake To Samsung Biologics For $2.3B

Biogen Inc (NASDAQ: BIIB) is selling its stake in a pharmaceutical joint venture with the South Korean conglomerate Samsung for $2.3 billion.

1 … 8 9 10 11

Organisations

Securities and Exchange Commission

Federal Trade Commission

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play